Chlamydia pneumoniae DNA is present in peripheral blood mononuclear cells during acute coronary syndrome and correlates with chlamydial lipopolysaccharide levels in serum

References

• Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002; 2: 11–7
   PubMed Web of Science ®Google Scholar
• Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983–6
   PubMed Web of Science ®Google Scholar
• Johnston SC, Messina LM, Browner WS, Lawton MT, Morris C, Dean D. C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke 2001; 32: 2748–52
   PubMed Web of Science ®Google Scholar
• Erkkila L, Laitinen K, Haasio K, Tiirola T, Jauhiainen M, Lehr HA, et al. Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection. Atherosclerosis 2004; 177: 321–8
   PubMedGoogle Scholar
• Blessing E, Campbell LA, Rosenfeld ME, Chough N, Kuo CC. Chlamydia pneumoniae infection accelerates hyperlipidaemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 2001; 158: 13–7
   PubMed Web of Science ®Google Scholar
• Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747–53
   PubMedGoogle Scholar
• Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA, Stassen FR, Vliegen I, Grauls GE, et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Cardiovasc Res 2002; 56: 269–76
   PubMedGoogle Scholar
• Boman J, Soderberg S, Forsberg J, Birgander LS, Allard A, Persson K, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998; 178: 274–7
   PubMed Web of Science ®Google Scholar
• Tiirola T, Jaakkola A, Bloigu A, Paldanius M, Sinisalo J, Nieminen MS, et al. Novel enzyme immunoassay utilizing lipopolysaccharide-binding protein as a capture molecule for the measurement of chlamydial lipopolysaccharide in serum. Diagn Microbiol Infect Dis 2006; 54: 7–12
   PubMedGoogle Scholar
• Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827–32
   PubMed Web of Science ®Google Scholar
• Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002; 105: 1555–60
   PubMed Web of Science ®Google Scholar
• Tong CY, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993; 46: 313–7
   PubMed Web of Science ®Google Scholar
• Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492–503
   PubMed Web of Science ®Google Scholar
• Huittinen T, Leinonen M, Tenkanen L, Manttari M, Virkkunen H, Pitkanen T, et al. Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk. Arterioscler Thromb Vasc Biol 2002; 22: 431–7
   PubMed Web of Science ®Google Scholar
• Tiirola T, Sinisalo J, Nieminen MS, Silvennoinen-Kassinen S, Paldanius M, Saikku P, et al. Chlamydial lipopolysaccharide is present in serum during acute coronary syndrome and correlates with CRP levels. Atherosclerosis 2007; 194: 403–7
   PubMedGoogle Scholar
• Wang SS, Tondella ML, Bajpai A, Mathew AG, Mehranpour P, Li W, et al. Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease. Int J Cardiol 2007; 118: 215–9
   PubMedGoogle Scholar
• Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435–9
   PubMedGoogle Scholar
• Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646–54
   PubMed Web of Science ®Google Scholar
• Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351–6
   PubMed Web of Science ®Google Scholar
• Blessing E, Campbell LA, Rosenfeld ME, Chesebro B, Kuo CC. A 6-week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae. J Antimicrob Chemother 2005; 55: 1037–40
   PubMed Web of Science ®Google Scholar
• Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003; 108: 261–5
   PubMed Web of Science ®Google Scholar
• Erkkila L, Jauhiainen M, Laitinen K, Haasio K, Tiirola T, Saikku P, et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005; 49: 3959–62
   PubMed Web of Science ®Google Scholar
• Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K, Surcel HM, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25: 499–505
   PubMed Web of Science ®Google Scholar
• Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002; 15: 1–20
   PubMed Web of Science ®Google Scholar
• Lajunen T, Vikatmaa P, Ikonen T, Lepantalo M, Lounatmaa K, Sormunen R, et al. Comparison of polymerase chain reaction methods, in situ hybridization, and enzyme immunoassay for detection of Chlamydia pneumoniae in atherosclerotic carotid plaques. Diagn Microbiol Infect Dis 2008; 61: 156–64
   PubMedGoogle Scholar